Reference Values and Determinants of Fractional Exhaled Nitric Oxide in a Representative Adult Population in Western Sweden
Abohalaka, Reshed; Ercan, Selin; Lehtimäki, Lauri; Özuygur Ermis, Saliha Selin; Lisik, Daniil; Bashir Awad Bashir, Muwada; Jadhav, Radhika; Ekerljung, Linda; Wennergren, Göran; Lötvall, Jan; Pullerits, Teet; Backman, Helena; Rådinger, Madeleine; Nwaru, Bright I.; Kankaanranta, Hannu (2025-09)
Abohalaka, Reshed
Ercan, Selin
Lehtimäki, Lauri
Özuygur Ermis, Saliha Selin
Lisik, Daniil
Bashir Awad Bashir, Muwada
Jadhav, Radhika
Ekerljung, Linda
Wennergren, Göran
Lötvall, Jan
Pullerits, Teet
Backman, Helena
Rådinger, Madeleine
Nwaru, Bright I.
Kankaanranta, Hannu
09 / 2025
Clinical And Translational Allergy
e70107
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-2025112811029
https://urn.fi/URN:NBN:fi:tuni-2025112811029
Kuvaus
Peer reviewed
Tiivistelmä
Background: Fractional exhaled nitric oxide (FENO) is used to differentiate asthma inflammatory phenotypes and guide its management. However, data on FENO reference values in a representative adult population is limited. We aim to derive reference values and determinants of FENO in a representative adult population. Methods: The West Sweden Asthma Study is a clinical-epidemiological population-representative study of randomly selected adults in Western Sweden. From this cohort, 943 subjects participated in comprehensive clinical investigations, including skin prick testing (SPT), specific immunoglobulin E (sIgE) analysis, and FENO measurement. Clinical allergy was defined as co-occurrence of atopy (positivity to SPT or sIgE) and self-reported allergic symptoms to the same allergen family. FENO levels were analysed in relation to the presence or absence of clinical allergy, asthma, and other factors. Results: The 95th percentile of FENO ranged from 34 parts per billion (ppb) in those between 30 and 40 years old to 52 ppb in those ≤ 30 years old in the entire sample (N = 943), and from 26 to 37 ppb in those without clinical allergy, asthma, or chronic obstructive pulmonary disease (COPD) (n = 587), depending on age. Sex, smoking, clinical allergy, atopy, asthma, and hypertension influenced FENO levels, meanwhile, age, asthma, clinical allergy, and reversibility-related variables were significant determinants of FENO levels. Conclusion: The 95th percentile (upper normal limit) for FENO ranges from 34 to 52 ppb overall, and from 26 to 37 ppb in those without clinical allergy, asthma, or COPD, depending on age. These findings provide a guide for interpreting FENO in the general population.
Kokoelmat
- TUNICRIS-julkaisut [23470]
